Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,278 | 105 | 1,167 |
| Samples | 160 | 25 | 130 |
| Peptides | 155 | 16 | 140 |
Function
TGIF1 · TGFB induced factor homeobox 1
The protein encoded by this gene is a member of the three-amino acid loop extension (TALE) superclass of atypical homeodomains. TALE homeobox proteins are highly conserved transcription regulators. This particular homeodomain binds to a previously characterized retinoid X receptor responsive element from the cellular retinol-binding protein II promoter. In addition to its role in inhibiting 9-cis-retinoic acid-dependent RXR alpha transcription activation of the retinoic acid responsive element, the protein is an active transcriptional co-repressor of SMAD2 and may participate in the transmission of nuclear signals during development and in the adult. Mutations in this gene are associated with holoprosencephaly type 4, which is a structural anomaly of the brain. Alternative splicing has been observed at this locus and multiple splice variants encoding distinct isoforms are described. [provided by RefSeq, Jul 2013].
Isoforms & Proteins
14 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000618001 | Q15583-3 | 148 | 117 |
| ENST00000343820 | Q15583-2 | 136 | 103 |
| ENST00000407501 | Q15583-2 | 118 | 96 |
| ENST00000401449 | Q15583-4 | 113 | 90 |
| ENST00000345133 | Q15583-4 | 112 | 90 |
| ENST00000400167 | Q15583-4 | 112 | 90 |
| ENST00000405385 | Q15583-4 | 112 | 90 |
| ENST00000472042 | Q15583-4 | 112 | 90 |
| ENST00000548489 | Q15583-4 | 112 | 90 |
| ENST00000551541 | Q15583-4 | 112 | 90 |
| ENST00000551402 | F8W1J9* | 43 | 34 |
| ENST00000577543 | J3KS32* | 38 | 32 |
| ENST00000330513 | Q15583-4 | 6 | 5 |
| ENST00000552383 | F8VWK5* | 4 | 4 |
Gene Properties
Recurrent Mutations
All 118 amino-acid changes on canonical ENST00000618001 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TGIF1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TGIF1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Colorectal Carcinoma | 6/143 4% | 39/3239 1% |
| Endometrial Carcinoma | 2/42 5% | 6/612 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Melanoma | 1/210 0% | 12/1899 1% |
| Plasma Cell Myeloma | 0/44 0% | 2/305 1% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Other Solid Cancers | 2/94 2% | 6/1515 0% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 3/810 0% |
| Gastric Carcinoma | 2/74 3% | 4/1809 0% |
| Hepatocellular Carcinoma | 1/46 2% | 6/2210 0% |
| Ewings Sarcoma | 0/63 0% | 1/262 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 7/2550 0% |
| Other Sarcomas | 0/69 0% | 2/699 0% |
| Thyroid Gland Carcinoma | 2/45 4% | 2/1592 0% |
| Head and Neck Carcinoma | 1/85 1% | 3/1574 0% |
| Non-Cancerous | 0/104 0% | 2/830 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 3/1390 0% |
| Breast Carcinoma | 0/144 0% | 5/3264 0% |
| Neuroblastoma | 0/87 0% | 2/1331 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Other Blood Cancers | 0/61 0% | 3/2725 0% |
| Kidney Carcinoma | 0/85 0% | 2/1862 0% |
Mutation Distribution
Where TGIF1 is mutated · all tissues, split by cell line vs tissue
How many mutations in TGIF1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,278 mutations in TGIF1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|